Exciting Developments in Clinical Research: Axcellant's Groundbreaking Global Study
Axcellant, a European CRO in Warsaw, announces a groundbreaking clinical trial in nuclear medicine that could change standard care, impacting over 20 million US patients and 200 million worldwide. The trial, supported by leading US experts, aims to develop a new radioactive compound as a diagnostic agent, with FDA approval for the study plan.
Reference News
Axcellant, a European CRO in Warsaw, announces a groundbreaking clinical trial in nuclear medicine that could change standard care, impacting over 20 million US patients and 200 million worldwide. The trial, supported by leading US experts, aims to develop a new radioactive compound as a diagnostic agent, with FDA approval for the study plan.
Axcellant, a European CRO in Warsaw, announces a groundbreaking nuclear medicine trial. The trial aims to innovate diagnostics for millions of patients globally. Led by CEO Wojciech Kula, the study involves 20 US sites and collaboration with US experts. FDA inspections affirm Europe's suitability for high-quality clinical trials.